Clinical evaluation demonstrates safety and tolerability of cyclosporin A in refractory Kawasaki disease, indicating a promising rescue therapy.
CyA treatment is considered safe and well tolerated, and a promising option for patients with refractory KD. Further investigations will be needed to clarify optimal dose, safety, and timing of CyA treatment.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: